Anti-Infectives · LP-036
Erythromycin Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-036Anti-Infectives
- Generic identity
- ErythromycinTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-036
- Generic identity
- Erythromycin
- Presentation
- Tablet
- Catalogue strength
- 250 mg; 500 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: erythromycin.
- Dosage form: tablet.
- Proposed strengths: 250 mg and 500 mg.
- General catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Exact erythromycin chemical form/basis for each strength.
- Coating, score/divisibility and immediate/modified-release character; none may be assumed from “tablet”.
- Strength-to-pack/SKU mapping and quantitative excipient composition.
- Approved indication, interaction/QT/liver warnings, storage, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 250 mg | Tablet — chemical form/release character not established | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | Do not infer erythromycin form, coating or release type. |
| B | 500 mg | Tablet — chemical form/release character not established | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | Do not infer erythromycin form, coating or release type. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Erythromycin is a macrolide antibiotic used for selected infections caused by susceptible bacteria. The precise chemical form, release characteristics and authorized indication can differ among oral products. It should not be treated as a universally interchangeable alternative to every other macrolide or penicillin. This page explains ingredient background for professional readers and does not establish Luang Pharma approved labeling, equivalence or availability.
Clinical context and therapeutic role
Selection depends on the organism, infection site, allergy history, local guidance and whether another antibiotic offers a more appropriate balance of benefit and risk. A complete medication review is especially important because erythromycin can alter the exposure of other medicines. The prescriber should consider hepatic disease and cardiac rhythm risk before selecting therapy. Persistent infection or intolerance requires review of diagnosis and treatment rather than unsupervised substitution.
Selected safety context
Nausea, vomiting, abdominal cramps and diarrhoea are common. Erythromycin can prolong the QT interval, cause liver injury and produce important metabolic interactions. Medicines affecting heart rhythm, some statins and other interacting treatments need review. Severe diarrhoea, jaundice, fainting, palpitations or an extensive rash requires prompt assessment. A history of serious macrolide allergy must be disclosed. The tablet description alone does not establish whether a particular product may be crushed or split.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: ErythromycinArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 28 July 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-036.
Professional enquiries
Request product-specific evidence for LP-036.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.